Login / Signup

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.

Marloes VerstappenH W van SteenbergenP H P de JongA H M van der Helm-van Mil
Published in: Arthritis research & therapy (2022)
ACPA-negative RA patients with early DAS remission and a strong biomarker response (or baseline CRP levels ≥ 3× ULN) are most likely to achieve SDFR later on. This could guide personalized decisions on DMARD tapering/cessation in ACPA-negative RA.
Keyphrases
  • disease activity
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • ankylosing spondylitis
  • interstitial lung disease
  • clinical trial
  • combination therapy
  • study protocol
  • smoking cessation
  • replacement therapy